Novel diagnostic and prognostic biomarkers in esophageal cancer.

Expert opinion on medical diagnostics Pub Date : 2013-11-01 Epub Date: 2013-10-04 DOI:10.1517/17530059.2013.843526
Patrick S Plum, Elfriede Bollschweiler, Arnulf H Hölscher, Ute Warnecke-Eberz
{"title":"Novel diagnostic and prognostic biomarkers in esophageal cancer.","authors":"Patrick S Plum,&nbsp;Elfriede Bollschweiler,&nbsp;Arnulf H Hölscher,&nbsp;Ute Warnecke-Eberz","doi":"10.1517/17530059.2013.843526","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This article provides an overview of actual biomarkers with an impact on improvement of diagnosis and treatment of esophageal cancer patients.</p><p><strong>Areas covered: </strong>Recent literature has been analyzed and provides information regarding the potential role of molecular markers as a diagnostic or prognostic factor in esophageal cancer.</p><p><strong>Expert opinion: </strong>Until now, the role of molecular markers is far from being firmly established for routine use and is not without obstacles. However, with reliable standardized methods, established cut-off values and promising candidates in marker panels with markers of genetic, epigenetic and proteomic origin might result in a marker tool worthwhile of being validated in large, prospective, randomized trials. Novel validated marker combinations have to be clinically applied to prove their putative role in complementing clinical techniques within the development of better detection concepts of esophageal cancer, improving patients' long-term prognosis by early and purposive therapy within individualized treatment concepts.</p>","PeriodicalId":72996,"journal":{"name":"Expert opinion on medical diagnostics","volume":"7 6","pages":"557-71"},"PeriodicalIF":0.0000,"publicationDate":"2013-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1517/17530059.2013.843526","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert opinion on medical diagnostics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1517/17530059.2013.843526","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/10/4 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 8

Abstract

Introduction: This article provides an overview of actual biomarkers with an impact on improvement of diagnosis and treatment of esophageal cancer patients.

Areas covered: Recent literature has been analyzed and provides information regarding the potential role of molecular markers as a diagnostic or prognostic factor in esophageal cancer.

Expert opinion: Until now, the role of molecular markers is far from being firmly established for routine use and is not without obstacles. However, with reliable standardized methods, established cut-off values and promising candidates in marker panels with markers of genetic, epigenetic and proteomic origin might result in a marker tool worthwhile of being validated in large, prospective, randomized trials. Novel validated marker combinations have to be clinically applied to prove their putative role in complementing clinical techniques within the development of better detection concepts of esophageal cancer, improving patients' long-term prognosis by early and purposive therapy within individualized treatment concepts.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新的食管癌诊断和预后生物标志物。
本文综述了对食管癌患者的诊断和治疗有影响的实际生物标志物。涵盖领域:最近的文献分析并提供了关于分子标记作为食管癌诊断或预后因素的潜在作用的信息。专家意见:到目前为止,分子标记的作用还远远没有被确定为常规使用,也不是没有障碍。然而,通过可靠的标准化方法,在具有遗传、表观遗传和蛋白质组起源标记的标记面板中建立临界值和有希望的候选标记,可能会导致值得在大型、前瞻性、随机试验中验证的标记工具。新的经过验证的标志物组合必须在临床上应用,以证明其在补充临床技术方面的假定作用,在发展更好的食管癌检测概念方面,在个性化治疗概念中通过早期和有目的的治疗改善患者的长期预后。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Simtomax, a novel point of care test for coeliac disease. Diagnosis of skeletal muscle channelopathies. Review of latent and lytic phase biomarkers in Kaposi's sarcoma. The precision study: examining the inter- and intra-assay variability of replicate measurements of BGStar, iBGStar and 12 other blood glucose monitors. Novel diagnostic and prognostic biomarkers in esophageal cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1